Financials RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret
Equities
RTALB
TRERTAL00018
Pharmaceuticals
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.13 TRY | +0.41% | -4.34% | -15.41% |
Valuation
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Capitalization 1 | 65.14 | 41.06 | 83.75 | 1,241 | 951.4 | 1,299 |
Enterprise Value (EV) 1 | 49.8 | 35.51 | 80.91 | 1,247 | 843.9 | 1,219 |
P/E ratio | 15.7 x | 69.9 x | 15 x | 19.1 x | 8.31 x | 4.62 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 1.69 x | 2.01 x | 5 x | 5.39 x | 2.48 x | 15.1 x |
EV / Revenue | 1.3 x | 1.73 x | 4.83 x | 5.41 x | 2.2 x | 14.2 x |
EV / EBITDA | 11.9 x | -3.28 x | -52.6 x | 23.1 x | 8.49 x | -996 x |
EV / FCF | -98.4 x | -3.38 x | -14.2 x | -42.5 x | 22.1 x | -13.1 x |
FCF Yield | -1.02% | -29.6% | -7.02% | -2.36% | 4.52% | -7.62% |
Price to Book | 1.2 x | 0.71 x | 0.97 x | 8.26 x | 3.04 x | 2.18 x |
Nbr of stocks (in thousands) | 54,922 | 54,922 | 84,012 | 95,415 | 100,000 | 100,000 |
Reference price 2 | 1.186 | 0.7477 | 0.9969 | 13.01 | 9.514 | 12.99 |
Announcement Date | 12/03/18 | 11/03/19 | 04/03/20 | 11/03/21 | 11/03/22 | 13/03/23 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net sales 1 | 38.45 | 20.47 | 16.77 | 230.4 | 384.3 | 86.03 |
EBITDA 1 | 4.177 | -10.82 | -1.539 | 54.03 | 99.37 | -1.224 |
EBIT 1 | 3.046 | -11.71 | -2.767 | 52.48 | 95.42 | -7.79 |
Operating Margin | 7.92% | -57.19% | -16.5% | 22.77% | 24.83% | -9.06% |
Earnings before Tax (EBT) 1 | 4.358 | -2.227 | 3.952 | 87.99 | 147.4 | 302.5 |
Net income 1 | 4.158 | 0.6012 | 4.423 | 60.93 | 114.5 | 281.1 |
Net margin | 10.81% | 2.94% | 26.38% | 26.44% | 29.78% | 326.78% |
EPS 2 | 0.0757 | 0.0107 | 0.0666 | 0.6811 | 1.145 | 2.811 |
Free Cash Flow 1 | -0.5059 | -10.5 | -5.682 | -29.36 | 38.11 | -92.91 |
FCF margin | -1.32% | -51.28% | -33.89% | -12.74% | 9.92% | -108% |
FCF Conversion (EBITDA) | - | - | - | - | 38.35% | - |
FCF Conversion (Net income) | - | - | - | - | 33.29% | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 12/03/18 | 11/03/19 | 04/03/20 | 11/03/21 | 11/03/22 | 13/03/23 |
Balance Sheet Analysis
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | 5.11 | - | - |
Net Cash position 1 | 15.3 | 5.56 | 2.85 | - | 107 | 79.6 |
Leverage (Debt/EBITDA) | - | - | - | 0.0945 x | - | - |
Free Cash Flow 1 | -0.51 | -10.5 | -5.68 | -29.4 | 38.1 | -92.9 |
ROE (net income / shareholders' equity) | 7.58% | -0.59% | 6.29% | 61.6% | 49.8% | 59% |
ROA (Net income/ Total Assets) | 3.07% | -11.3% | -2.11% | 18.5% | 14.7% | -0.75% |
Assets 1 | 135.4 | -5.305 | -209.5 | 329.4 | 776.4 | -37,318 |
Book Value Per Share 2 | 0.9900 | 1.050 | 1.030 | 1.570 | 3.130 | 5.950 |
Cash Flow per Share 2 | 0.2800 | 0.1100 | 0.1500 | 0.1800 | 1.580 | 0.3100 |
Capex 1 | 0.32 | 2.22 | 5.19 | 16 | 21.4 | 12.7 |
Capex / Sales | 0.83% | 10.84% | 30.96% | 6.93% | 5.58% | 14.8% |
Announcement Date | 12/03/18 | 11/03/19 | 04/03/20 | 11/03/21 | 11/03/22 | 13/03/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-15.41% | 37.5M | |
-1.13% | 89.37B | |
+2.76% | 40.65B | |
-12.32% | 32.81B | |
+52.41% | 25B | |
-17.39% | 15.29B | |
-42.45% | 11.61B | |
-10.48% | 11.49B | |
+6.14% | 8.98B | |
-7.72% | 8.23B |
- Stock Market
- Equities
- RTALB Stock
- Financials RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret